

**GDSD 2025**

# **DATA-DRIVEN MEDICINE**

**PROF. ANNE SCHWERK**

- **INTERNATIONAL UNIVERSITY OF APPLIED SCIENCES**
- **CHARITÉ / BERLIN INSTITUTE OF HEALTH**



---

## Overview: AI and Healthcare Data

---

## Examples

---

## Take-Home-Message

---

**1**


**2**

**3**


---

#1

# Overview: AI and Healthcare Data




# INCREASED RELEVANCE OF MEDICAL AI PUBLICATIONS





# ADOPTION OF AI PER INDUSTRY

Levels of AI maturity by industry, 2021 and 2024\*



Notes: \* 2024 = estimated scores. Industries' AI maturity scores represent the arithmetic average of their respective Foundational and Differentiation index.


Source: Accenture Research



**statista**




# LACK OF DIGITALISATION



STAGE	<div> <div>himss Analytics</div> <div>EMRAM</div> </div> <div>EMR Adoption Model Cumulative Capabilities</div>
7	Complete EMR; External HIE; Data Analytics, Governance, Disaster Recovery, Privacy and Security
6	Technology Enabled Medication, Blood Products, and Human Milk Administration; Risk Reporting; Full CDS
5	Physician documentation using structured templates; Intrusion/Device Protection
4	CPOE with CDS; Nursing and Allied Health Documentation; Basic Business Continuity
3	Nursing and Allied Health Documentation; eMAR; Role-Based Security
2	CDR; Internal Interoperability; Basic Security
1	Ancillaries - Laboratory, Pharmacy, and Radiology/Cardiology information systems; PACS; Digital non-DICOM image management
0	All three ancillaries not installed


## CHALLENGES: HEALTHCARE DATA

- Lack of data & inhibited sharing:
  - Labeled data
  - Benchmark data sets & open data
  - Data silos
  - Lack of cross-validation options
  - Lack of standardization/ interoperability
- Data quality:
  - Imbalanced data
  - Missing data
  - Incomplete data
  - Standardization




# HEALTHCARE DATA INCREASE

2018-2025 Data  
Compound Annual Growth Rate (CAGR)






**Artificial Intelligence:** IT systems with human-like behavior – based on statistical & mathematical models



# THE END OF THEORY - DEDUCTION VERSUS INDUCTION



## Deduction

1. Hypothesis

2. Experiment

3. Data collection

4. Data analysis

5. Validation



## Induction

1. Big Data  
Integration


2. Data mining


3. Pattern recognition

4. Hypothesis  
generation

5. Validation

# IMPORTANCE OF DATA: DATA QUALITY







Source: <https://fedbiomed.org/>

- **Data protection:** Data remains at the original location - only model **parameters** are shared
- **Decentralization:** Hospitals train local models and send **encrypted parameters** to central coordinators
- **Iterative process:** The coordinator aggregates local models into a global model and shares it. The process is repeated until the model converges


- Initiated by the Medical Informatics Initiative (MII) launched in 2016 by the BMBF
- A federated network for centralized and decentralized data access
- Core data set from primary IT systems of the universities → local data integration centers
- Standardization to MII format
- Depending on the basis of use:
  - Distributed evaluations
  - Central evaluations (with broad consent)





- 15 M EHRs
- 160 M Diagnoses
- 1.5 Billion Lab values
- **2-3 M uncoded rare diseases**




Open data and collaborative  
networks




Data analytics and ML for  
personalized medicine.



Real-world data for medical  
innovations




Data integration and analysis



#2

# Examples

# RARE DISEASES: DIAGNOSTIC ODYSSEY



## Rare Disease Dilemma

Most rare diseases are genetic

72%

Most rare diseases affect children

75%

Many are misdiagnosed

70%

On average it takes 8 years to diagnose

8 years

# DATA AVAILABILITY

- FDPG Data
- Orpha / ICD Codes



**L1:**

FDPG Data  
Diagnosis codes

**L2:**

- 1) Diagnosis codes
- 2) Minimal core data


**L3:**

- 1) Diagnosis codes
- 2) Minimal core data
- 3) Stand. details


- Addition through clinics
- **Goal:** Europe-wide analysis

- Special data:
  - Progress data
  - Intervention data
  - PROMs
  - Omics
- European Registers


# ML FOR RARE DISEASE (RD) DIAGNOSTICS



- Undected RDs
- EHR-based Phenotypes
- **Example:** Morbus Osler




- Combined markers
- Cheaper Diagn.
- **Novel Diagnoses:**
- Combined: Genetic (PRS) Epigenetic



- Precision medicine
- Treatment

- Monitoring
- Interventions
- Progression
- Diagnostics





- Hereditary disease: ALPL gene mutation
- 400 + disease-causing ALPL variants
- Symptoms:
  - **Severe:** Bone demineralization, respiratory failure, seizures
  - **Mild:** Tooth loss, periodontal disease
- Diagnosis: Ø 5.7 years delayed
  - Frequent misdiagnoses
  - ALP value + symptoms + genetics
  - Specific orpha code
- Incorrect treatment: bisphosphonates → Bone damage

→ **Early diagnosis is crucial**

**L1 Analysis:** Use ALP (+PLP) biomarkers + phenotypes to determine more specific biomarker thresholds  
→ identify new patients and improve diagnostic precision




- Hereditary disease: : ENG, ACVRL1, or SMAD4 gene mutation
- 600 + disease-causing variants
- Symptoms:
  - **Severe:** Arteriovenous malformations → Bleeding, strokes, cardiac stress
  - **Mild:** Nosebleeds (epistaxis), telangiectasias on skin and mucous membranes
- Diagnosis: Ø 26 years delayed
- Frequent misdiagnoses
- Curacao criteria + genetics
- Incorrect treatment: anticoagulants → Bleeding
- Early diagnosis is crucial




**L1 Analysis:** Using the ICD-10 code for identification & extended phenotyping  
→ RBS on Curacao Criteria → New identifications

## L3 DATA: OMICS




# OMICS DATA AND ANALYSES



## GWAS:


- Analyzes the **genomes** of large groups of people with and without a disease / trait
- Identifies genomic variants (SNPs) - by assessing linkage disequilibrium






# DIAGNOSTIC PRECISION: POLYGENIC RISK SCORE CALCULATION

- PRS sum weighted effect sizes of risk variants from GWAS to estimate disease susceptibility
- Linear approach: does not account for complex genetic interactions (e.g., epistasis)
- **ML helps to:**
  - Account for non-linear interactions
  - Combine multiple existing PRS





GWAS

Top genetic variants  
e.g. SNPs  
(largest effect size)



Risk scoring

# COST PER GENOME AND PRECISION MEDICINE PUBLICATIONS



- **Genetic newborn screening:**


- Early diagnosis of genetic RDs

- **Digital tools:**

- Symptom checker
- EHR algorithms

- **Infrastructure:**

- Federated ML



**Improved the accuracy and speed of diagnosis**

#3

# —Take-Home-Message & Discussion

— **AI as a medical game changer:**

- Access to digital data
- High quality data

— **Expected AI revolution:**

- Fastest growing healthcare data source
- Text data and LLMs





# THANK YOU



Prof. Dr. Anne Schwerk



[anne.schwerk@iu.org](mailto:anne.schwerk@iu.org)